Literature DB >> 18075237

Chronological changes of CD4(+) and CD8(+) T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis.

Yoshifumi Sonobe1, Shijie Jin, Jinyan Wang, Jun Kawanokuchi, Hideyuki Takeuchi, Tetsuya Mizuno, Akio Suzumura.   

Abstract

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS). The etiology of MS remains unclear, but T cells specific for myelin components, such as myelin oligodendrocyte glycoprotein (MOG), are thought to play a critical role in the onset of MS. Experimental autoimmune encephalomyelitis (EAE) has been used as an animal model of MS, and T helper type 1 (Th1) cells play an essential role for the pathogenesis of EAE through the production of Th1 cytokines, interferon-gamma (IFN-gamma) and tumor necrosis factor-alpha (TNF-alpha). We examined CD4(+) and CD8(+) T cell responses in the spleen and CNS of EAE mice, generated by immunization with a peptide (35-55 amino acid residues) of MOG. The number of both CD4(+) and CD8(+) T cells and their MOG-reactivity in the CNS were associated with increasing disease severity but not those in the spleen, suggesting that the MOG-specific CD4(+) and CD8(+) T cells in the CNS are involved in the development of EAE. Polymerase chain reaction analysis suggested that both CD4(+) and CD8(+) T cells produced IFN-gamma and TNF-alpha, while CD4(+) T cells also produced interleukin-17 (IL-17), an important factor in the development of EAE. Thus, CD4(+) T cells may contribute to the induction of EAE by producing IL-17. Furthermore, CD8(+) T cells express higher levels of a suppressive cytokine, IL-10. Taking together, our data suggest that CD4(+) T cells are involved in the early phase of EAE, whereas CD8(+) T cells have a regulatory role in the later stage of EAE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18075237     DOI: 10.1620/tjem.213.329

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  21 in total

Review 1.  Molecular Mechanisms of the Action of Vitamin A in Th17/Treg Axis in Multiple Sclerosis.

Authors:  Mina Abdolahi; Parvaneh Yavari; Niyaz Mohammadzadeh Honarvar; Sama Bitarafan; Maryam Mahmoudi; Ali Akbar Saboor-Yaraghi
Journal:  J Mol Neurosci       Date:  2015-08-30       Impact factor: 3.444

2.  Enhancing the ability of experimental autoimmune encephalomyelitis to serve as a more rigorous model of multiple sclerosis through refinement of the experimental design.

Authors:  Mitchell R Emerson; Ryan J Gallagher; Janet G Marquis; Steven M LeVine
Journal:  Comp Med       Date:  2009-04       Impact factor: 0.982

Review 3.  Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.

Authors:  Insha Zahoor; Shailendra Giri
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

4.  Lineage-Specific Metabolic Properties and Vulnerabilities of T Cells in the Demyelinating Central Nervous System.

Authors:  Scott M Seki; Max Stevenson; Abagail M Rosen; Sanja Arandjelovic; Lelisa Gemta; Timothy N J Bullock; Alban Gaultier
Journal:  J Immunol       Date:  2017-05-15       Impact factor: 5.422

5.  Age of the donor reduces the ability of human adipose-derived stem cells to alleviate symptoms in the experimental autoimmune encephalomyelitis mouse model.

Authors:  Brittni A Scruggs; Julie A Semon; Xiujuan Zhang; Shijia Zhang; Annie C Bowles; Amitabh C Pandey; Kathleen M P Imhof; Allan V Kalueff; Jeffrey M Gimble; Bruce A Bunnell
Journal:  Stem Cells Transl Med       Date:  2013-09-09       Impact factor: 6.940

6.  The novel small-molecule TPN10456 inhibits Th17 cell differentiation and protects against experimental autoimmune encephalomyelitis.

Authors:  Cuixia Yang; Jie Lv; Xiangrui Jiang; Zhenglong Xiang; Ran Gong; Jiahua Xing; Guangyu Liu; Ling Xie; Kandireya Saimaier; Yan Zhang; Junjian Wang; Hu Shen; Juping Pan; Jingshan Shen; Changsheng Du
Journal:  Cell Mol Immunol       Date:  2020-10-27       Impact factor: 11.530

7.  Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics.

Authors:  Rahmawati Ridwan; Paul Kiptoo; Naoki Kobayashi; Scott Weir; Michael Hughes; Todd Williams; Rondang Soegianto; Teruna J Siahaan
Journal:  J Pharmacol Exp Ther       Date:  2009-12-21       Impact factor: 4.030

8.  Interleukin-25 expressed by brain capillary endothelial cells maintains blood-brain barrier function in a protein kinase Cepsilon-dependent manner.

Authors:  Yoshifumi Sonobe; Hideyuki Takeuchi; Kunio Kataoka; Hua Li; Shijie Jin; Maya Mimuro; Yoshio Hashizume; Yasuteru Sano; Takashi Kanda; Tetsuya Mizuno; Akio Suzumura
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

9.  Rapamycin Augments Immunomodulatory Properties of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Encephalomyelitis.

Authors:  Mansoureh Togha; Mehrdad Jahanshahi; Leila Alizadeh; Soodeh Razeghi Jahromi; Gelareh Vakilzadeh; Bahram Alipour; Ali Gorji; Amir Ghaemi
Journal:  Mol Neurobiol       Date:  2016-03-12       Impact factor: 5.590

10.  Inhibition of midkine alleviates experimental autoimmune encephalomyelitis through the expansion of regulatory T cell population.

Authors:  Jinyan Wang; Hideyuki Takeuchi; Yoshifumi Sonobe; Shijie Jin; Tetsuya Mizuno; Shin Miyakawa; Masatoshi Fujiwara; Yoshikazu Nakamura; Takuma Kato; Hisako Muramatsu; Takashi Muramatsu; Akio Suzumura
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.